ResMed Provides Update on Phase III SERVE-HF Study of Adaptive Servo-Ventilation (ASV) Therapy In Central Sleep Apnea and Chronic Heart Failure
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/5/2026
Go back to ResMed Provides Update on Phase III SERVE-HF Study of Adaptive Servo-Ventilation (ASV) Therapy In Central Sleep Apnea and Chronic Heart Failure
May 14, 2015 10:19 AM EDT
Jefferies maintains a Hold rating on ResMed (NYSE: RMD), and lowered the price target to $52.00 (from $65.00), following SERVE Heart Failure trial. Analyst Raj Denhoy said that the trial showed an increase in cardiovascular mortality in low EF heart failure patients. "The finding all but ends... More
May 13, 2015 8:44 AM EDT
BofA/Merrill Lynch downgraded ResMed (NYSE: RMD) from Buy to Neutral. Earlier ResMed announced that SERVE-HF, a multinational, multicenter, randomized controlled Phase III trial did not meet its primary endpoint.
For an analyst ratings summary and ratings history on ResMed... More
May 13, 2015 6:14 AM EDT
ResMed (NYSE: RMD) announced that SERVE-HF, a multinational, multicenter, randomized controlled Phase III trial did not meet its primary endpoint. SERVE-HF was designed to assess whether the treatment of moderate to severe predominant central sleep apnea with Adaptive Servo-Ventilation (ASV) therapy could reduce mortality and morbidity in patients with symptomatic chronic heart failure in addition to optimized medical care.
The study did not show a statistically significant difference between patients randomized to ASV therapy and those in the control group in the primary endpoint of time to all-cause mortality or unplanned hospitalization... More
